BeOne Medicines Ltd. (ONC) Financial Analysis & Valuation | Quarter Chart
BeOne Medicines Ltd. (ONC)
ONCPrice: $310.25
Fair Value: 🔒
🔒score
BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies. Founded in 2010 and headquartered in Cambridge, Massachusetts—with operations spanning over 45 countries across six continents—the company reb... more
BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, dev... more
Description
Shares
| Market Cap | $33.15B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Pharmaceuticals |
| Country | US | CEO | John V. Oyler |
| IPO Date | 2016-02-02 | CAGR | 0.67% |
| Employees | 11,000 | Website | beonemedicines.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
ONC chart loading...
Fundamentals
Technicals
| Enterprise Value | $29.31B | P/E Ratio | 70.35 |
| Forward P/E | 30.12 | PEG Ratio | — |
| P/S Ratio | 6.53 | P/B Ratio | 10.87 |
| P/CF Ratio | 40.12 | P/FCF Ratio | 34.12 |
| EPS | $4.42 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 37.44% | Gross Margin | 0.87% |
| Operating Margin | 0.12% | Profit Margin | 0.09% |
| ROE | 0.12% | ROA | 0.06% |
| ROCE | 0.1% | Current Ratio | 3.64 |
| Quick Ratio | 3.27 | Cash Ratio | 2.67 |
| Debt/Equity | 0.43 | Interest Coverage | 12.79 |
| Altman Z Score | 5.55 | Piotroski Score | 7 |